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Summary
Objectives: Matrix metalloproteinases (MMPs) and aggrecanases are essential players in cartilage degradation. However, the signaling path-
ways that results in MMP and/or aggrecanase synthesis and activation are not well understood. We investigated the molecular events leading
to MMP- and aggrecanase-mediated cartilage degradation.
Methods: Cartilage degradation was induced in bovine articular cartilage explants by oncostatin M (OSM) and tumor necrosis factor (TNF), in
the presence or absence of speciﬁc inhibitors of the mitogen-activated protein kinases (MAPKs) P38, P44/42 and Src family. Toxicity was
followed by the AlamarBlue colorimetric assay. MMP-activity was assessed using a ﬂuorescent substrate assay and MMP-9 and -2 activities
by gelatinase zymography. MMP-mediated collagen type II degradation and MMP as well as aggrecanase-mediated aggrecan degradation
was investigated with speciﬁc ELISA and hydroxyproline release by standard methods. The ﬁndings were veriﬁed by immunohistochemistry
and histology.
Results: Stimulation of cartilage degradation by OSMþ TNF resulted in 100-fold induction of CTX-II release (P< 0.01). This was dose-depen-
dently inhibited by MAPK P38 inhibitors and by the MAPK P44/42 inhibitors. MMP-activity and expression was signiﬁcantly decreased, as
evaluated by cleavage of ﬂuorescence MMP-substrate and zymography. Immunohistochemistry conﬁrmed these ﬁndings. Interestingly,
only the P44/42 inhibitors abrogated aggrecanase-mediated aggrecan degradation.
Conclusion: We found that inhibition of MAPK P38, P44/42 and Src family abrogated proteolytic cartilage degradation by blocking MMP syn-
thesis and activity. However, only MAPK P44/42 was essential for aggrecanase-mediated aggrecan degradation. These data suggest that
various aspects of cartilage degradation can be targeted independently by inhibiting speciﬁc upstream signaling pathway.
ª 2009 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
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and proteoglycans of which aggrecan is the most abundant1.
The key enzymes of cartilage destruction have been identi-
ﬁed as thematrix metalloproteinases (MMPs) and the closely
related a disintegrin and metalloproteinase with thrombo-
spondin motifs (ADAM-TS)2e8. Aggrecan is degraded by
both MMPs and ADAM-TSs, aggrecanases, whereas colla-
gen type II is degraded primarily by various MMPs2e10. The
proteolytic activity of these enzymes results in cartilage deg-
radation and in the concomitantly releaseof various extra-cel-
lular fragments such as neo-epitopes that can be measured
both in vitro and in vivo9. Recently developed tools for quan-
tifying these neo-epitopes may aid in understanding the
processes taking place during the pathogenesis of joint
degenerative diseases. One example is the immunoassay,
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279at the C-terminal telopeptide end (CTX-II)10e13. Although as-
says for measuring sulphated glycosaminoglycans (sGAGs)
are available, they do not distinguish between synthesis
and degradation of the proteoglycans9. Furthermore, sGAG
assays do not distinguish MMP-mediated degradation of ag-
grecan that generates DIPEN341 and 342FFGVG fragments14
from aggrecanase-mediated degradation that generates
ITEGE373 and 374ARGSV fragments15. Tools quantifying
each of these fragments have recently been developed, and
have been applied in mechanistic studies16,17.
Inﬂammation and cytokines play an important role in
rheumatoid arthritis (RA) and in some cases of osteoarthri-
tis (OA). It has been shown that cytokines can induce
aggrecan degradation, inhibit proteoglycan synthesis and
induce expression and activation of MMPs, aggrecanases
and cathepsins18,19. Among the most studied and well-
known cytokines are tumor necrosis factor (TNF)-a, oncos-
tatin M (OSM) and interleukin-1 (IL-1). These cytokines play
a vital role in inﬂammatory responses in RA and have been
shown in various settings to induce catabolic responses in
OA that leads to cartilage destruction20e23. A deeper under-
standing of the mechanisms leading to these imbalances in
280 B.-C. Sondergaard et al.: Signaling pathways in cartilage degradationthe extra-cellular matrix turnover of affected joints may
come from investigation of the signaling pathways responsi-
ble for catabolic responses.
The signaling pathways leading to mitogen-activated pro-
tein kinase (MAPK) activation have been linked to various
catabolic responses in other diseases24, but their role in
cartilage degenerative diseases is less understood. The
MAPKs have received increasing attention, in part due to
the availability of speciﬁc inhibitors that allow their function
to be studied25,26. The MAPK P38 and P44/42 inhibitors,
SB-202190 and U-0126, respectively, are more speciﬁc26
and less toxic inhibitors than the previously used SB-
203580 and PD-9805925. These, and a vast array of other
emerging inhibitory compounds, may enable detailed
molecular investigation of the important signaling pathways
occurring in articular chondrocytes that leads to irreversible
cartilage destruction in joint degenerative diseases.
Bovine articular cartilage explants exposed to catabolic
cytokines such as OSMþ TNF are useful ex vivo models
of cartilage degradation with a high in vivo-likeness, since
the extra-cellular matrix is intact and contains all the regula-
tors and natural structural components of articular carti-
lage27. The molecular mechanisms behind articular
cartilage degradation can be investigated under these
settings10,15,16,28e30.
In the present studies we investigated the roles of the
MAPKs P38, P44/42 and kinases from the Src family in
the activation and expression of proteases responsible for
cartilage degradation. We focused on the molecular mech-
anisms leading to either MMP- or aggrecanase-mediated
cartilage degradation.Materials and methodsPREPARATION OF ARTICULAR CARTILAGE EXPLANTSBovine articular cartilage explants from cows aged 1.5 years were cul-
tured in six replicates for 21 days with refreshment of medium with addition
of kinase inhibitors and cytokines three times a week. Cartilage degradation
was induced by a combination of the catabolic cytokines, 10 ng/ml OSM
(SigmaeAldrich, DK) and 20 ng/ml TNF (R&D Systems Inc., US). Some ex-
plants were treated with cytokines alone and to other conditions MAPK inhib-
itors were added in combination with the cytokines to investigate the effect
on cartilage degradation. The P38 MAPK inhibitors SB-202190, SB-
203580, the P44/42 MAPK inhibitors PD-98059, U-0126; or the Src family
inhibitor, PP1 (Biomol International L.p., US) were added to the catabolically
stimulated cultures in concentrations of 0.1, 1 or 10 mM. The inhibitor vehicle
DMSO was tested at all doses in combination with cytokines and did not
show any effects (data not shown). Explants cultured in DMEM without treat-
ment served as controls. To investigate the non-chondrocyte mediated
effects and the passive diffusion of fragments to the conditioned medium,
other cartilage explants were metabolically inactivated by three freeze/
thaw cycles in liquid nitrogen followed by thawing in a 37C water bath,
and subsequently cultured in medium.INVESTIGATION OF TOXICITYThe cell-viability was examined on the last day of culture using the Ala-
marBlue colorimetric assay (Invitrogen, DK). In brief, AlamarBlue solution
was diluted 10% with the respective refreshed treatments of the cartilage
explants and incubated with the cartilage explants for 2 h. The ﬂuorescence
was measured at 540 nm and 590 nm.COLLAGEN TYPE II DEGRADATIONHydroxyproline
Hydroxyproline released from the cartilage to the conditioned medium
was quantiﬁed and used as a measure of collagen type II degradation. For
quantiﬁcation 50 mg/mL L-hydroxyproline dissolved in 1 mM hydrochloric
acid was used in a 2-fold dilution series as standard. A 10 mL of conditioned
medium from each treatment was hydrolyzed with 40 mL 7.5 M hydrochloric
acid for 20 h at 110C. Then the samples were spun for 2 min at 3000 rpmand left at 50C until all liquid had totally evaporated. The samples were
re-suspended in 1:2 MilliQ water/isopropanol. Controls were made from bo-
vine bone slices decalciﬁed in 15% EDTA solution and digested in 10 mg/mL
collagenase. Next 10 mL samples, controls or standards were added and
oxidized for 4 min with 10 mL/well perchlor acid/citric acid buffer, and subse-
quently 130 mL/well of the chromogen 4-methyl-benzaldehyde/isopropanol
solution was added. The plates were incubated for 25 min at 60C, cooled
to room temperature, and absorbance was read at 558 nm.
CTX-II
Cartilage degradation measured as collagen type II degradation was
quantitatively measured using the CTX-II ELISA, Urine PC-CartiLaps CTX-
II (IDS Ltd., UK). CTX-II measurements were performed according to the as-
say standard instructions. CTX-II is a speciﬁc biochemical marker of collagen
type II breakdown and detects a neo-epitope, which can be generated by
a broad-spectrum of proteases including MMP-1, -3, -7, -9 and -1331.MMP-ACTIVITYTotal MMP-activity assay
Quantitative evaluation of the total MMP-activity in the conditioned
medium was assessed using the MMP-substrate Mca-Pro-Leu-Gly-Leu-
Dap(Dnp)-Ala-Arg-NH2 (Bachem, UK) with a quencher and a highly ﬂuores-
cent end. The substrate was used in a 2 mM concentration and 1:4
conditioned medium were added to the buffer: 0.01 M CaCl2, 0.2 M NaCl,
0.05 M Tris HCl, 50 mM ZnSO4, 0.05% Triton X-100, at pH 7.5, modiﬁed
from Ridnour et al.32 for 10 min at 37C, with shaking. Upon cleavage of
the quenching moiety the ﬂuorescence was measured at 328 nm excitation
and 392 nm emission. The general MMP inhibitor GM6001 [20 mM] (AM
Scientiﬁc, US) was used as negative control.
Gelatinase zymography
MMP-activity and expression were investigated using gelatinase zymog-
raphy. Conditioned medium were adjusted according to their protein
concentration (BioRad, US) and applied for gel-electrophoresis on 10%
SDS-polyacrylamide gel using the substrate 0.5 mg/mL gelatin (SigmaeAl-
drich, UK). After electrophoresis, gels were washed three times before incu-
bation overnight at 37C with gentle agitation in 0.1% Triton X-100, 5 mM
CaCl2, 3 mM NaN3, 50 mM Tris, and pH 7.4. Gels were stained for 30 min
with a solution containing 0.25% Coomassie R-250 (SigmaeAldrich, UK)
with 10% acetic acid and 45% methanol. They were then destained in a so-
lution of 20% methanol, 17% ethanol, and 0.6% diethyl-ether for 30 min until
clear bands were obtained. Gels were ﬁnally soaked in 2% glycerol, dried be-
tween cellophane membranes and scanned for documentation.AGGRECAN DEGRADATION342-G2 ELISA
MMP-mediated aggrecan degradation was measured in the conditioned
medium with the 342FFGVG-G2 sandwich ELISA (IDS Ltd., UK). The
ELISA uses the monoclonal antibody AF28 as a catching antibody, which
recognizes the N-terminal MMP-cleaved neo-epitope 342FFGVG localized
in the inter-globular domain. Detection and visualization is conducted
with the secondary peroxidase conjugated monoclonal antibody F78 that
has high afﬁnity for a repetitive sequence within the second globular
domain (G2)15.
374-G2 ELISA
The degradation of aggrecan by aggrecanases is in particular mediated
by ADAM-TS-4 and -533. This was measured using an ELISA detecting
the aggrecanase-generated aggrecan neo-epitope 374ARGSV utilizes two
monoclonal antibodies in a sandwich ELISA system (IDS Ltd., UK). The as-
say combines the mouse BC-3 antibody (Abcam, UK) as a capturing anti-
body that recognizes the neo-epitope and the F78-POD antibody, as
described above, which detects epitopes in the G2 globular domains of
aggrecan15.HISTOLOGY AND IMMUNOHISTOCHEMISTRYAlcian blue staining was used to visualize the proteoglycans retained in
the matrix and immunohistochemistry using the CTX-II antibody (IDS Ltd.,
UK) as an indicator of collagen type II degradation. The cultured cartilage ex-
plants were ﬁxed with formaldehyde, processed in a Tissue-Tek VIP, embed-
ded in parafﬁn blocks and cut into 5 mm sections. For detection of
Fig. 1. The effect of P38-inhibition on cell-viability and collagen type
II degradation. Bovine articular cartilage explants were cultured in
the presence of cytokines OSMþ TNF (Oþ T) and P38 inhibitors
(SB-202190). (A) Cell-viability. The viability of the chondrocytes
was investigated before termination of the each experiment after
21 days of culture using the AlamarBlue dye. (B) Shows the release
of collagen fragments by measuring the release of hydroxyproline
(OHpyr) and (C) shows the degradation of collagen type II (CTX-II)
281Osteoarthritis and Cartilage Vol. 18, No. 3proteoglycans, sections were deparafﬁnized, rehydrated and stained using
1% alcian blue (SigmaeAldrich, UK), a tetravalent-cation-dye binding to
charged polymers such as proteoglycans. CTX-II-immunolocalization was
performed by blocking unspeciﬁc binding with 0.5% casein and subsequently
incubated with monoclonal CTX-II antibody in a 1:5000 dilution10. The im-
mune-reaction was visualized by mouse Envision (DAKOcytomation, DK)
and 3.30-diaminobenzidine (DABþ) (SigmaeAldrich, UK). The sections
were counterstained in Ehrlich’s hematoxylin. Sections were photographed
on an Olympus-BX-60 microscope equipped with an Olympus-DP71-camera
using CellA-software.STATISTICAL ANALYSISResults are shown as meanþ S.E.M. All in vitro experiments were con-
ducted with six replicates. Differences between mean values were compared
by ANOVA using Bartlett’s test for equal variance followed by Dunnett’s mul-
tiple comparison test (a¼ 0.05) using the GraphPad Prism-software.ResultsEFFECT OF P38 MAPK INHIBITORS ON COLLAGEN TYPE II
DEGRADATION AND CHONDROCYTE VIABILITYTo investigate potential effects of the P38 MAPK inhibitors
and to exclude effects due to cyto-toxicity, an AlamarBlue
cell-viability colorimetric assay was performed on the bovine
cartilage explants at day 21 [Fig. 1(A)]. No signiﬁcant de-
crease in viability was observed between cells from explants
treated with the cytokine combination OSMþ TNF and the
P38 inhibitor SB-202190, and those treated with cytokines
alone. The metabolically inactivated cartilage explants had
no viable cells as expected (P< 0.001) whereas the cyto-
kine-treated explants had 30% decreased viability, com-
pared with untreated controls, as previously observed10.
Cultured medium from cytokine-stimulated explants con-
tained 200-fold (P< 0.001) increased levels of hydroxypro-
line at day 21 than the control [Fig. 1(B)]. The passive
diffusion of hydroxyproline from metabolically inactivated
chondrocytes did not contribute notably to the total release
of hydroxyproline. A signiﬁcant dose-dependent decrease
in hydroxyproline levels, by 73%, 97% or 99% was ob-
served in medium treated with SB-202190 in doses of 0.1,
1 or 10 mM, respectively, when compared with cytokine
stimulation alone at day 21 (P< 0.001 for all doses). An-
other speciﬁc P38 MAPK inhibitor, SB-203580, produced
similar results at doses of 0.1, 1 or 10 mM with a reduction
in the release of hydroxyproline to the medium at day 21
by 82%, 90% and 99% respectively, compared with levels
after treatment with the OSMþ TNF combination alone
(data not shown).
To investigate protease-activities responsible for the colla-
gen degradation the MMP-mediated collagen type II frag-
ment, CTX-II, was assessed9. As seen in Fig. 1(C), CTX-II
fragmentswere increased 25-fold during cytokine stimulation
of explants compared with the untreated control (P< 0.001).
The cytokine-induced CTX-II release was completely abro-
gated by 1 and 10 mM SB-202190 100%, P< 0.001 and
reduced by 71% at 0.1 mM (P< 0.001), as observed in
Fig. 1(C). A similar reduction by 71% (P< 0.001) and 78%
(P< 0.001) compared with cytokine-treated explants was
observed in the presence of 0.1 and 1 mM SB-203580,
respectively, at day 21 (data not shown).in the conditioned medium from day 21, which was concentration-
dependently inhibited by SB-202190. All bars represent the mean
value of six replicates and were adjusted for the weight of the indi-
vidual cartilage explants, presented with the standard error of mean
(S.E.M.). The asterisks represent the level of statistical signiﬁcant
difference from the Oþ T treatment, ***P< 0.001.
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SYNTHESIS AND ACTIVITY OF MMPS AND DEGRADATION
BY AGGRECANASESPrevious experiments have shown that the cytokine
combination is capable of inducing MMP expression and
activation in chondrocytes10,34. To investigate whether the
decreased collagen type II degradation was due to de-
creased MMP-activity, we quantiﬁed the total MMP-activity
with a synthetic ﬂuorescent MMP-substrate, and MMP-2
and -9-activity by gelatin zymography, previously applied
to visualize both pro- and active forms10.
MMP-activity, quantiﬁedusingasynthetic ﬂuorescentMMP-
substrate and MMP-2 and -9-activity by gelatin zymography,
was increased by 200% at day 21 in medium from explants
treated with the OSMþ TNF cytokine combination compared
with the untreated control [Fig. 2(A)]. Metabolically inactivatedFig. 2. The effects of P38 MAPK-inhibition on MMP-activity and expressio
with the cytokines OSMþ TNF (Oþ T) and co-cultured with the SB-20219
rescent MMP speciﬁc substrate and (B) by gelatinase zymography. The ba
metabolic inactivated cartilage. (C) MMP-generated fragments of aggrec
culture by the 342-G2 ELISA and (D) released aggrecanase-mediated fra
The bars represent the mean value of six replicates adjusted for the am
***P< 0.0explants showed similarly low MMP-activity as the control. A
statistically signiﬁcant andconcentration-dependent decrease
in MMP-activity was observed at day 21 by 43% (P< 0.001),
65% (P< 0.001) and 67% (P< 0.001) for 0.1, 1 and 10 mM
of the P38 MAPK inhibitor SB-202190 respectively, when
compared to OSMþ TNF-stimulated explants.
As observed in Fig. 2(B), clear bands of MMP-2 andMMP-
9 expression were detected in conditioned medium from
OSMþ TNF-stimulated explants. In alignment with the re-
duction in total MMP-activity, both bands for MMP-2 and -9
were dose-dependently decreased by SB-202190. These re-
sults are in direct support of the hydroxyproline, CTX-II, and
MMP-activity data, supporting the notion that P38 MAPK is
involved in the synthesis and expression of MMPs.
In order to investigate whether the decreased MMP-activity
in addition was associated with a decreased aggrecann. Conditioned medium from articular cartilage explants stimulated
0 inhibitor of MAPK P38, was investigated by (A) cleavage of a ﬂuo-
nd sizes of MMP-9 and MMP-2-activity are indicated on the gel. MI:
an were evaluated in the conditioned medium from the last day of
gments of aggrecan were evaluated at day 6 by the 374-G2 ELISA.
ount of cultured cartilage and the standard error of mean (S.E.M.).
01.
283Osteoarthritis and Cartilage Vol. 18, No. 3degradation we employed the 342-G2 ELISA quantifying the
neo-epitope 342FFGVG combined with the G2 domain of ag-
grecan, quantifying MMP-mediated aggrecan degradation.
Furthermore, another assay was used to investigate aggreca-
nase-mediated aggrecan degradation, the 374-G2 assay16.
Assays measuring aggrecan degradation showed that
cytokine-stimulated explants had a more than 150-fold in-
creased 342-G2 level compared with control [Fig. 2(C)].
The addition of SB-202190 (0.1 mM) to OSMþ TNF reduced
342-G2 by 74% (P< 0.001) and the 1 and 10 mM doses of
SB-202190 completely abrogated (P< 0.001) MMP-gener-
ated fragments. The effect of SB-202190 on aggrecanase-
mediated aggrecan degradation was evaluated by
measuring the levels of 374-G2 by ELISA15, see Fig. 2(D).
In cytokine-stimulated cartilage, levels of the 374-G2 bio-
chemical marker of aggrecanase-mediated aggrecan degra-
dation were increased 4-fold compared with control. The
addition of the P38 inhibitor SB-202190 did not signiﬁcantly
lower 374-G2 levels comparedwith cytokine stimulation only.THE EFFECT OF P38 MAPK-INHIBITION ON PROTEOGLYCAN
AND COLLAGEN TYPE II LOSSTo further investigate the role of P38 in proteolytic acti-
vated cartilage explants on proteoglycan and collagen turn-
over, we assessed the proteoglycan content by histology
and immunolocalization of the CTX-II neo-epitope.
As observed in Fig. 3, the alcian blue staining on cartilage
stimulated with catabolic cytokines was less intense than
the metabolically inactive or the untreated control. The ad-
dition of SB-202190 at the highest dose (10 mM) protected
the proteoglycan content, as can be seen from the more in-
tense blue staining compared with explants subjected to cy-
tokine stimulation alone. A similar response was observed
with SB-203580 (data not shown). Immunolocalization of
the CTX-II antibody was observed in the catabolically stim-
ulated cartilage explants matrix, as shown in Fig. 3, lower
panel. In explants simultaneously treated with cytokines
and (10 mM) SB-202190, the localization of CTX-II was ab-
rogated, which correlates with the ﬁnding in CTX-II levels by
ELISA. Alcian blue stains the GAGs (Fig. 3), which are
either attached to the proteoglycans (e.g., aggrecan) or re-
tained in the matrix as pseudo-free sugar chains. In con-
trast, the neo-epitope markers 342-G2 and 374-G2 are
aggrecan- and metalloproteinase-speciﬁc and can therefore
only be associated with GAGs indirectly. It should be notedFig. 3. Histology and immunohistochemistry. Articular cartilage was cultu
the effect of MAPK P38-inhibition, by three doses of SB-202190. In order
formaldehyde ﬁxed, parafﬁn embedded and sectioned slides were stained
the CTX-II antibody, which recognizes the CTX-II neo-epitopes in cleave
brown color. 20 mthat neither histology nor immunohistochemistry are quanti-
ﬁable. The amount of color should therefore not be scaled.THE EFFECTS OF P44/42 INHIBITORS ON CATABOLICALLY
STIMULATED CARTILAGE EXPLANTSThe catabolic cytokines have previously been shown to
induce the MAPK P44/42 pathway35,36. We further investi-
gated the effect of MAPK P44/42-inhibition by U-0126 or
PD-98059 on MMP- and aggrecanase-mediated cartilage
destruction.
Figure 4(A) shows the effect on cell-viability measured by
AlamarBlue. The highest dose (10 mM) U-0126 signiﬁcantly
decreased cell-viability in articular cartilage explants com-
pared with stimulation by OSMþ TNF cytokines alone
(P< 0.01), whereas other doses had no signiﬁcant effect.
The release of hydroxyproline to the cultured medium at
day 21 was signiﬁcantly increased by the catabolic cytokines
compared to control [Fig. 4(B)]. The MAPK P44/42 inhibitor
U-0126 in combinationwith cytokines signiﬁcantly decreased
the concentration of hydroxyproline in the conditioned me-
dium by 74% (P< 0.001) and 85% (P< 0.001) at doses of
0.1 mM, and 1 mM.As seen in Fig. 4(C), the cytokines induced
MMP-activity by 100% compared to control. U-0126 reduced
the MMP-activity in the presence of cytokines by 39%
(P< 0.001) and 48% (P< 0.001) at doses of 0.1 mM, and
1 mM, respectively. This was veriﬁed by gelatinase zymogra-
phy as visualized in Fig. 4(D). The cytokine-stimulated ex-
plants had 45-times higher 342-G2 levels compared to
control [Fig. 4(E)]. Doses of 0.1 and 1 mM U-0126 reduced
the 342-G2 levels of MMP-generated aggrecan fragments
by 36%and44%.All doses ofU-0126 signiﬁcantly decreased
the 10-fold cytokine induced aggrecanase-mediated carti-
lage degradation although no concentration-dependent re-
sponse was observed [Fig. 4(F)].
In summary, U-0126 signiﬁcantly decreased MMP-activ-
ity, MMP- and aggrecanase-mediated degradation at 0.1,
1 and 10 mM dose. However, at the highest concentration
only, signiﬁcant reductions in cell-viability were observed.
Thus, the lower concentrations suggest a speciﬁc effect of
the P44/42 MAPK inhibitor of proteolytic activities.THE EFFECTS OF SRC KINASE-INHIBITION OF ARTICULAR
CARTILAGE DEGRADATIONTo investigate whether some pathwaysmay be responsible
for onlyMMP-or aggrecanase-activitywe tested theSrc familyred with catabolic cytokines OSMþ TNF for 3 weeks to investigate
to visualize the retained proteoglycans in the cultured cartilage, the
by alcian blue. Other sections were used for immunolocalization by
d collagen type II molecules and is visualized in the panel by the
agniﬁcation.
Fig. 4. Effects of inhibition of the MAPK P44/42 pathway on catabolic stimulated articular cartilage. The cytokines OSMþ TNF (Oþ T) were
used in articular cartilage explants to induce cartilage degradation. Inhibitors of the P44/42 MAPK pathway (U-0126) were used in three doses
and the effects were investigated. (A) Effects on cell-viability were investigated by AlamarBlue and the highest dose (10 mM) lowered the met-
abolic activity. Graph (B) shows the levels of released hydroxyproline (OHpyr) to the conditioned medium at the last day of culture. The effects
on MMP-activity and expression in the conditioned medium is shown in graph (C) by MMP cleavage of a ﬂuorescent MMP-substrate and (D)
expression of pro- and active MMP-9 and -2 by gelatinase zymography. MI, metabolic inactivated cartilage. Graph (E) and (F) show the effect
of P44/42 MAPK-inhibition on aggrecan degradation by on day 21 MMP (342-G2 ELISA) and aggrecanase-mediated degradation at day 6
(374-G2 ELISA), respectively. The bars represent the mean value of six replicates adjusted to the amount of cultured cartilage and the stan-
dard error of mean (S.E.M.). *P< 0.05, ***P< 0.001 compared to Oþ T treatment.
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Fig. 5. Effects of inhibition of the Src MAPK pathway on catabolic stimulated articular cartilage. The cytokines OSMþ TNF (Oþ T) was used in
articular cartilage explants to induce cartilage degradation. An inhibitor of the Src pathway PP1 were used in three doses and the effects in-
vestigated. (A) Effects on cell-viability were investigated by AlamarBlue colorimetric assay. Graph (B) shows the levels of released hydrox-
yproline (OHpyr) in the conditioned medium at the last day of culture. (C) The effects on MMP-activity in the conditioned medium at day
21 are shown in the graph by MMP cleavage of a ﬂuorescent MMP-substrate. Graph (D) and (E) show the effect of Src-inhibition on aggrecan
degradation by MMP at day 21 (342-G2 ELISA) and aggrecanase-mediated degradation at day 6 (374-G2 ELISA), respectively. The bars
represent the mean value of six replicates adjusted to the amount of cultured cartilage. The error bars indicate the standard error of mean
(S.E.M.). *P< 0.05, ***P< 0.001 compared to Oþ T treatment.
285Osteoarthritis and Cartilage Vol. 18, No. 3inhibitor PP1, as previously described37e39. As expected, the
metabolic inactivated explants had no viable cells when com-
pared to control (P< 0.001). The cytokines OSMþ TNF in-
duced release of hydroxyproline from the cartilage explants
to the conditioned medium by 366-fold compared to control(P< 0.001) [Fig. 5(B)]. The addition of 1 mMPP1 caused a re-
duction of 76% compared to cytokine-stimulated explants
(P< 0.001) in hydroxyproline release. The 10 mM PP1 dose
abrogated (99% reduction,P< 0.001) the release of hydroxy-
proline compared with OSMþ TNF-treated cartilage. As seen
Fig. 6. Schematic overview. Illustration of the potential molecular
signaling pathways of cytokine (OSMþ TNF) stimulated chondro-
cytes leading to proteolytic activity. Inhibition of the MAPK P44/42
pathway by either U-0126 or PD-98059 leads to abrogation of the
expression and activity of MMPs and aggrecanases and ADAM-
TS. Inhibitors of the P38 MAPK and Src pathways were also inves-
tigated by SB-203580 or SB-202190 and PP1, respectively.
Inhibition of these pathways resulted in inhibition of MMP expres-
sion and activity but did not inﬂuence ADAM-TSs activity.
286 B.-C. Sondergaard et al.: Signaling pathways in cartilage degradationin Fig. 5(C), treatment with cytokines inducedMMP-activity by
228% (P< 0.001) compared to control, while the addition of
0.1, 1 and 10 mM PP1 signiﬁcantly and dose-dependently
reduced this by 22% (P< 0.05), 56% (P< 0.001) and 73%
(P< 0.001), respectively. Treatment with 0.1 and 1 mM PP1
decreased the release of the MMP-mediated aggrecan frag-
ments 342-G2 by 35% and 36% compared to cytokine treat-
ment alone, although the difference was not signiﬁcant
[Fig. 5(D)]. Only the highest dose 10 mM PP1 signiﬁcantly ab-
rogated (98%,P< 0.05) the release. Asshown inFig. 5(E), cy-
tokine stimulation increased the release of aggrecanase-
mediated aggrecan fragments to the conditioned medium by
500% (P< 0.001) compared to control. Interestingly, whereas
a complete inhibition ofMMP-mediated aggrecan degradation
was observed in the highest dose of PP1, no inhibitionwas ob-
served foraggrecanase-mediatedaggrecandegradation.This
strongly suggests that some pathways may result in both
MMP- and aggrecanase-mediated cartilage degradation
whereas other pathways may only result in cartilage degrada-
tion by one of the enzyme families. This hypothesis is summa-
rized in a schematic illustration (Fig. 6).
Discussion
Joint degenerative diseases can partly be described as
an imbalance between cartilage synthesis and degradation.
For the discovery and development of new treatments,
further understanding of the processes leading to disease
progression and in particular, the pathways leading to the
expression of the vast proteolytic enzymatic battery respon-
sible for MMPs, aggrecanases and cartilage destruction are
of pivotal importance.
These studies are the ﬁrst to demonstrate that: (1) MAPK
activity is a key upstream signaling event in processes lead-
ing to articular cartilage destruction and that both MAPK
P38 and P44/42-activities are essential for MMP expression
and activity; (2) Only MAPK P44/42 signaling was essential
for aggrecanase-mediated degradation; (3) inhibition of Srckinase signaling abrogated MMP-activity but not aggreca-
nase-activities. This suggests a direct linear pathway to
the P38-activity in articular cartilage. These investigations
are the ﬁrst to demonstrate potential divergence in these
pathways with respect to the key enzymes responsible for
articular cartilage degradation, as proposed in the sche-
matic Fig. 6.
It has previously been shown that protease-activities and
cell phenotype and fate are strongly dependent on the extra-
cellular environment35,36. The current investigations relied on
bovine articular cartilage cultures in which the chondrocytes
were embedded in their natural matrix and their phenotype
preserved, and thus may better predict in vivo responses
than mono-layer cultures with de-differentiated chondrocytes
or chondrocyte cell-lines. This experimental setup, combined
with novel ELISAs speciﬁc for given protease-activities, facili-
tated exploration at a molecular level of extra-cellular matrix
degradation caused by speciﬁc protease-activities, down-
stream to their distinct signaling pathways.
Studies in human cells have suggested that MAPK signal-
ing is important for the MMP-derived catabolic response of
chondrocytes. Liacini et al. showed that TNF-stimulated hu-
man OA chondrocytes up-regulated expression of MMP-13,
through MAPK 44/42 and Janus-NH2-terminal kinase
JNK37. Similar results in human chondrosarcoma cells sup-
ported these ﬁndings38. Taken together, these ﬁndings sug-
gest that MAPK signaling is important for the MMP-derived
catabolic response of chondrocytes.
Recently an in vivo proof-of-concept model it was demon-
strated that intra-articular injections of the P38 MAPK inhib-
itor SB-203580 in the anterior cruciate ligament transection
(ACLT) rat model of OA inhibited the expression of MMP-3
and MMP-13 and protected against cartilage damage39.
Other research showed IL-1 stimulated collagen degrada-
tion but not aggrecan degradation and was inhibited by
the P38 inhibitor SB-20358040, a scenario which is in com-
plete alignment with the present data. Also in alignment with
our data, IL-1 driven MMP-13 induction in isolated chondro-
cytes and chondrosarcoma cells was demonstrated to be
dependent on P38-activity41.
Our results strongly suggest that aggrecanolysis and col-
lagenolysis may be separated by divergent upstream sig-
naling pathways. One key ﬁnding is that inhibition of P38
MAPK abrogated MMP-activity but did not affect aggreca-
nase-mediated cartilage destruction. A similar response
was found with Src kinase family inhibition, suggesting
these players to be in direct linear pathway. The role of
aggrecanases in cartilage degradation has only recently
received attention, and the pathways leading to aggreca-
nase-activity compared with those leading to MMP-activity
are not well understood. Inhibition of MAPK P44/42 abro-
gates both MMP- and aggrecanase-activity. This is the ﬁrst
investigation of pathways leading to aggrecanase-activity in
cartilage, and further a disassociation of the key signaling
events leading to expression and activity of the catabolic
players in articular cartilage destruction. Presently only
very limited information exists for pathways leading to
aggrecanase-activity42.
Src kinase-activity has on several occasions been dem-
onstrated to inﬂuence MAPK activities43,44. With respect
to the current ﬁndings, Src-inhibition abrogated MMP but
not aggrecanase-activities in a similar fashion to P38
MAPK-inhibition. This may suggest that at least in catabol-
ically activated chondrocytes, P38 and Src are in direct lin-
ear pathway, and Src-inhibition does not affect MAPK P44/
42-activities. Studies suggest that the Src family inhibitor
PP1 also can inhibit P38 MAPK in very low concentrations26
287Osteoarthritis and Cartilage Vol. 18, No. 3and from these studies it is not possible to discriminate
whether this inhibitor also directly inhibited the MAPK path-
way. The outline in Fig. 6 is currently a working hypothesis
and these preliminary observations need to be conﬁrmed by
additional investigations focusing on kinase-activities in
face of protease-activities.
A pathological understanding of these proteases, MMPs
and aggrecanases, and their roles are emerging. Cartilage
turnover is normally maintained by a balance between
catabolic and anabolic processes in which compensatory
mechanisms in response to altered biomechanical stresses
such as altered gait, weight distribution, or traumatic injury18
ensure homeostasis in normal healthy individuals. Develop-
ment of biochemical markers reﬂecting matrix turnover,
degradation and formation, is currently receiving increased
attention9. In particular matrix degradation products, spe-
ciﬁc products of enzymatic protein cleavage, neo-epitopes,
have received much attention, and resulted in a range of
novel markers. Some of these have recently been
reviewed9. Evidence suggests that these degradation frag-
ments of cartilage destruction may not only be viewed as
markers of matrix destruction, but might actually reﬂect a co-
ordinated sequence of events eventually leading to irrevers-
ible articular cartilage destruction. In particular, different
aggrecanase- or MMP-mediated aggrecan fragments have
been shown to reﬂect reversible and irreversible cartilage
destruction, respectively17.
Our group recently investigated the capacity of repair by
chondrocytes by analyzing their ability to initiate an anabolic
response subsequent to three different levels of catabolic
stimulation17. We found that cartilage degradation was
completely reversible in the presence of high levels of ag-
grecanase-mediated aggrecan degradation. However, after
induction of MMP-mediated aggrecan and collagen type II
degradation, the capacity for repair was completely lost
with regard to collagen type II synthesis, whereas proteogly-
can synthesis was strongly attenuated17. In context of the
present work, it may be of pivotal interest to dissociate
the pathways ensuring cartilage homeostasis and mainte-
nance in face of those pathological processes leading to ir-
reversible cartilage destruction. The current line of
investigations suggests that P38 MAPK activity could be as-
sociated with MMP-mediated irreversible cartilage damage,
whereas the processes needed for normal repair mecha-
nism and aggrecanase-activity may in part be controlled
by MAPK P44/42-activities. These suggestions and obser-
vations need to be investigated further to understand the
molecular processes of cartilage destruction.
As mentioned in the introduction MAPK inhibitors are of-
ten cell-toxic in higher concentrations. In the current study
the highest dose of U-126 lowered metabolic activity in
the cartilage explants, and hence the results from this
dose may not be due to speciﬁc inhibition. The stimulation
of cartilage degradation by the catabolic cytokine
OSMþ TNF usually lowers the metabolic activity. However
in Fig. 5(A), the metabolic activity increased slightly with the
cytokine treatment. This increase was not statistically signif-
icant, and may be related to the variation between experi-
ments due to use of primary cultures. The current
investigations do not aim to support the use of speciﬁc
MAPK inhibitors as possible treatment options for cartilage
degenerative diseases, but were initiated to gain a deeper
understanding of the signaling pathways involved in carti-
lage matrix degradation.
In conclusion, the current data clearly shows that MMP-
activity was almost abrogated in the presence of P38MAPK inhibitors whereas aggrecanase-activity only was at-
tenuated by MAPK P44/42-inhibition.Conﬂict of interest
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